StreetInsider.com News Articles

Chardan Starts Gossamer Bio Inc. (GOSS) at Buy

Tue, 13 Oct 2026 03:04:17 -0400

Chardan analyst Andreas Argyrides initiates coverage on Gossamer Bio Inc. (NASDAQ: GOSS) with a Buy rating and a price target of $160.00.

The analyst comments: “We initiate coverage of Gossamer Bio (GOSS) with a Buy rating and $160 price target. The bull case: FDA approves seralutinib, an inhaled PDGFRα/β, CSF1R and c-KIT inhibitor for add-on PAH therapy, on the totality of evidence despite Phase 3 PROSERA’s narrow statistical miss. The bear case: FDA holds Gossamer to PROSERA’s prespecified threshold and issues a CRL, with downside toward cash per share. The next inflection point is NDA acceptance in 4Q26, which de-risks the

Chardan Starts Gossamer Bio Inc. (GOSS) at Buy

Tue, 13 Oct 2026 03:04:17 -0400

Chardan analyst Andreas Argyrides initiates coverage on Gossamer Bio Inc. (NASDAQ: GOSS) with a Buy rating and a price target of $160.00.

Chardan Starts Gossamer Bio Inc. (GOSS) at Buy

Tue, 13 Oct 2026 03:04:17 -0400

Chardan analyst Andreas Argyrides initiates coverage on Gossamer Bio Inc. (NASDAQ: GOSS) with a Buy rating and a price target of $160.00.

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Thu, 08 Oct 2026 20:59:00 -0400

si-local-file:///var/storage/secattach/20261008/27168039.html

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Mon, 28 Sep 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20260928/27115845.html

Form 8-K Gossamer Bio, Inc. For: Sep 25

Mon, 28 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260928/27114392.html

Form 4 Gossamer Bio, Inc. For: Sep 23 Filed by: Milligan Sandra

Fri, 25 Sep 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260925/27108219.html

Form 4 Gossamer Bio, Inc. For: Sep 23 Filed by: Daniel Thomas O

Fri, 25 Sep 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260925/27108121.html

Form 4 Gossamer Bio, Inc. For: Sep 23 Filed by: Ciongoli Gregory Austin

Fri, 25 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260925/27108108.html

Form 4 Gossamer Bio, Inc. For: Sep 23 Filed by: Drynan Skye

Fri, 25 Sep 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260925/27108061.html

Form 4 Gossamer Bio, Inc. For: Sep 23 Filed by: Quisel John D

Fri, 25 Sep 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260925/27108031.html

Form 4 Gossamer Bio, Inc. For: Sep 23 Filed by: Cox Russell J.

Fri, 25 Sep 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260925/27107969.html

Form 4 Gossamer Bio, Inc. For: Sep 23 Filed by: Nathan Steven D

Fri, 25 Sep 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260925/27107850.html

Form 8-K Gossamer Bio, Inc. For: Sep 23

Wed, 23 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260923/27096777.html

Gossamer Bio files NDA with FDA for PAH drug seralutinib

Wed, 23 Sep 2026 16:01:27 -0400

Gossamer Bio, Inc. (Nasdaq: GOSS) submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib, a treatment for pulmonary arterial hypertension, according to a press release from the company.

The submission marks the company's first NDA and is supported by data from the Phase 3 PROSERA study, used as the primary adequate and well-controlled clinical investigation, along with confirmatory evidence from the Phase 2 TORREY study and additional supportive analyses.

The NDA follows a Pre-NDA Type B meeting between Gossamer and the FDA in June 2026. In its official written meeting minutes, the FDA characterized

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Wed, 23 Sep 2026 16:01:00 -0400

– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses –

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatment of PAH. This is the Company’s first NDA submission.

The NDA is supported

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Wed, 23 Sep 2026 16:01:00 -0400

– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses –

The NDA is supported

Form 3 Gossamer Bio, Inc. For: Sep 16 Filed by: Ciongoli Gregory Austin

Tue, 22 Sep 2026 18:28:00 -0400

si-local-file:///var/storage/secattach/20260922/27092101.html

Gossamer Bio Inc. (GOSS) PT Raised to $90 at H.C. Wainwright

Mon, 21 Sep 2026 07:35:51 -0400

H.C. Wainwright analyst Patrick Trucchio raised the price target on Gossamer Bio Inc. (NASDAQ: GOSS) to $90.00 (from $2.00) while maintaining a Buy rating.

Form 4 Gossamer Bio, Inc. For: Aug 24 Filed by: Hasnain Faheem